The NCI Developmental Therapeutics Program

Clinical Advances in Hematology and Oncology

Volumn 4, Issue 4, 2006, Pages 271-273

  Collins, Jerry M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL RESEARCH; DNA REPAIR; DRUG ABSORPTION; DRUG INDUSTRY; DRUG RESEARCH; DRUG SYNTHESIS; DRUG TARGETING; FINANCIAL MANAGEMENT; GASTROINTESTINAL ABSORPTION; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HUMAN; INTERNET; LABORATORY TEST; MEDICAL DECISION MAKING; PEER REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG SCREENING ASSAYS, ANTITUMOR; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; UNITED STATES;

EID: 33745207137     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Developmental Therapeutics Program of the NCI and NIH. http://dtp.nci.nih.gov.
2. Food and Drug Administration. Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies. January 2006. http://www.fda.gov/cder/guidance/7086fnl.pdf
3. Zubrod CG, Schepartz SA, Carter SK. Historical background of the National Cancer Institute's drug development thrust. Natl Cancer Inst Monogr. 1977;45:7-11.